About Event
Discover the 7th Cell Therapy Analytical Development Summit
Returning for its 7th edition, the Cell Therapy Analytical Development Summit now features two new focused tracks to tailor your learning by development stage, and enhance cross-functional collaborations. Bring representation from C-suite leaders to scientific and business development teams, to fast-track your pipeline progression!
The Early-Stage Analytical Development Track explores designing multi-assay potency matrices, advanced cellular kinetics, and future-proofing strategies for preclinical and Phase 1 programs. The Late-Stage Analytical Development Track covers transitioning assays to fully validated methods, managing late-stage changes through comparability planning, and leveraging clinical data to build robust potency and release assays for commercial readiness.
What Sets Us Apart in 2025?
ASCP/ACP-Accredited Flow Cytometry Training
Phase-Appropriate Learnings & Insights
Uniting the Full Analytical Landscape
Five Tangible Benefits You Will Walk Away with:
Supercharge your knowledge of novel tools to enhance predictive modeling and decode mechanism of action (MoA) from the start. Refine and validate your potency assays in later stages following learnings from Avobis Bio, Genentech, and Cellectis
Gain hands-on experience in designing GMP- and IVD-ready flow cytometry assays with SuperNova FlowCytometry to enhance your capabilities, meet stringent regulatory requirements and earn three CMLE credits
Optimize your sterility and microbial testing workflows by understanding US Pharmacopoeia’s new chapters and rapid test validation approaches, through insights from the National Institute of Health, BioNTech, Vertex Pharmaceuticals, and the University of Calgary
Streamline complex assay transfer and tech transfer processes with case studies from Quell Therapeutics and Dana Farber Cancer Institute, for faster validation, reduced transfer-related variability, and smoother commercial scale-up
Accelerate your understanding of current regulatory guidelines and updates by hearing from key opinion leaders at Bristol Myers Squibb, Cellectis and the National Institute of Standards & Technology
Connect with cell therapy experts working across analytical development, quality control and CMC to gain practical insights and tackle challenges from early-stage assay design through to late-stage validation and regulatory readiness
Who Will You Connect With?
Peers Insights:
This meeting offered a good mix of learning experiences for those new to analytical development, whilst also providing real-world advice from seasoned professionals, in more advanced stages. There were very experienced high-level executives who gave excellent talks and were very approachable
Associate Director, Analytical Development, New York Blood Center Enterprises, 2024 Attendee
The knowledge gained from the analytical and quality control space was a great. It was easy to interact with the people in the panel or in the round table, allowing for lots of networking opportunities and exchange of ideas and experiences
Manager, Johnson & Johnson, 2024 Attendee
